Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
BIOSYNGEN PTE. LTD.
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer
2024-02-01 17:41
Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA
2023-10-26 18:18
Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023
2023-09-18 17:53
Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors
2023-09-11 14:53
Biosyngen's First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation
2023-07-12 13:38
Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.
2023-07-12 10:32
Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore
2023-06-29 17:14
Biosyngen's Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer
2023-06-06 12:58
Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma
2023-04-18 19:03
Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma
2023-04-11 18:09
PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy
2023-03-29 22:53
Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer
2023-02-17 23:13
IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA
2022-12-15 13:08
The IND application of Biosyngen BRG01 Therapy was accepted by CDE
2022-09-28 18:05
Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost
2022-09-28 17:34
Embracing Win-win Cooperation - ASEAN Consul Generals, officials and representatives of chambers of commerce in Guangzhou visited Biosyngen
2022-05-28 09:00
French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City
2022-01-15 08:00
Biosyngen Pte Ltd launched biological production base for commercialization of immune cell therapeutics in China
2021-12-29 10:00
Singapore-based Biosyngen receives 500 million yuan in investment
2021-10-21 09:30
1